Paediatric SACT Regimens

Paediatric Chemotherapy regimens

The information contained in these regimens is a statement of consensus of NCCP and Consultant Paediatric Medical Oncologists and Paediatric Haematologist professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibility of the prescribing clinician and is subject to the terms of use.

Please email any comments or feedback on these regimens to

For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.

Paediatric Chemotherapy regimens

Regimen Indication

Blinatumomab Paediatric Therapy



As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogenic hematopoietic stem cell transplantation

Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy



As monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia (ALL) as part of the consolidation therapy.

Dinutuximab beta and Isotretinoin Therapy



For the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neurobasltoma, any actively progressing disease should be stabilised by other suitable measures.

Larotrectinib Monotherapy-Paediatric



For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
  • who have no satisfactory treatment options